Renal Angiomyolipoma

Earn CME/CE in your profession:

Continuing Education Activity

Renal angiomyolipomas (AMLs) are considered the most prevalent benign renal tumor. Renal AMLs are generally composed of blood vessels, smooth muscles, and adipose tissues. Although most of these tumors are found incidentally on radiological imaging, symptomatic presentations such as flank pain, gross hematuria, or severe retroperitoneal hemorrhage may also exist. Imaging plays a central role in the diagnosis and management of these tumors. This activity reviews the evaluation, treatment, complications, and prognosis of renal angiomyolipomas and highlights the role of the interprofessional team in evaluating and treating patients with this condition.


  • Describe the epidemiology of renal angiomyolipoma.
  • Review the evaluation of a renal angiomyolipoma.
  • Summarize the treatment of a renal angiomyolipoma.
  • Outline the complications associated with renal angiomyolipoma.


Renal angiomyolipomas (AMLs) are the most prevalent benign renal tumor.[1] First described by Grawitz in 1900, they are generally highly vascular, primarily composed of smooth muscle and adipose tissues, and are distinguished by perivascular epithelioid differentiation.[2] Although most of these tumors are found incidentally on radiological imaging, symptomatic presentations also exist. Typical symptoms would include flank pain, gross hematuria, and retroperitoneal hemorrhage, which can be severe.[3] 

Angiomyolipomas are sometimes mistakenly referred to as hamartomas. While both are benign, the difference is that an angiomyolipoma is a true tumor, while a hamartoma is defined as a disorganized collection of normal local tissue and cells that are usually the result of a trauma, infection, infarction, obstruction, or hemorrhage. Although first described by Grawitz, angiomyolipomas are distinct from Grawitz tumors which are malignant renal cell carcinomas and hypernephromas.

Imaging plays a central role in the diagnosis and management of renal angiomyolipomas.[4] The tumors contain variable amounts of the same three tissue elements (vascular, muscular, and adipose). Variations will have different pathological, radiological, and clinical features.[5] 

The fundamental diagnostic criterion of classic angiomyolipoma is detecting a large amount of adipose tissue on radiological imaging.[6] Although considered benign, the tumors may extend into the surrounding perirenal fat or renal sinus and nearby organs and lymphatics.[7] There are also rare, isolated reports of tumor thrombi extending through the renal vein into the vena cava.[8][9]

The management of angiomyolipomas is generally based on the clinical manifestations, tumor size, number, growth pattern, and malignant potential.[2][5] For example, epithelioid angiomyolipoma of the kidney is considered an uncommon subtype of angiomyolipoma, which is potentially malignant.[10]


Renal angiomyolipomas most often occur as "sporadic" cases (80%), which are isolated but may also be associated with certain "hereditary" conditions (20%) such as tuberous sclerosis and pulmonary lymphangioleiomyomatosis.[3][5] The exact reason behind the sporadic cases is not fully known, but some researchers postulate that it results from a spontaneous genetic mutation.[6] 

Hereditary angiomyolipomas, associated with tuberous sclerosis complex or pulmonary lymphangioleiomyomatosis, are caused by a genetic mutation in the TSC1 or TSC2 genes.[5][11] These mutations affect mTOR (mammalian target of rapamycin), which explains the response of these angiomyolipomas to mTOR inhibitors like sirolimus and everolimus.[12]

Compared to the more common sporadic type, hereditary angiomyolipomas (associated with tuberous sclerosis or lymphangioleiomyomatosis) are likely to be larger, begin at an earlier age, be multicentric and bilateral, grow more quickly, hemorrhage, develop chronic renal failure, and undergo malignant transformation.[13][14]

Tuberous sclerosis is a rare, familial, autosomal dominant genetic disorder that causes benign tumors to develop in various body parts, usually affecting the brain, eyes, heart, lungs, and kidneys. It is also associated with adenoma sebaceum, epilepsy, and mental deficiencies.[15] The overall incidence of tuberous sclerosis is estimated at about 1 per 10,000 population, although it is thought to be significantly underdiagnosed.[15] There is no racial or sexual preference for tuberous sclerosis.[15] More than 50% of patients with tuberous sclerosis will develop angiomyolipomas.[5] (See our companion article on Tuberous Sclerosis.)[15]

Patients with tuberous sclerosis tend to have larger angiomyolipomas when diagnosed (32% will be >3 cm), are more likely to have bilateral and multifocal lesions, and have twice the rate of tumors that increase in size over time compared to non-tuberous sclerosis AML patients.[16][17][18] They are also more likely to have the epitheliod variant type of angiomyolipoma, which is more likely to become malignant.[19] Among women with tuberous sclerosis, 40% will demonstrate some degree of pulmonary lymphangioleiomyomatosis, which is described below.[16][20][21]

Pulmonary lymphangioleiomyomatosis is an exceedingly rare genetic disease often associated with angiomyolipomas that may sometimes be associated with tuberous sclerosis. The overall incidence is about 5 cases per one million women.[22] It typically affects women of childbearing age by causing abnormal smooth muscle cell growth in the lungs, lymph nodes, and kidneys. In the lungs, it causes cysts which can affect pulmonary function resulting in dyspnea. In the kidneys, 45 to 60% of patients will develop angiomyolipomas that tend to be multiple and bilateral.[23][24][25] Pulmonary lymphangioleiomyomatosis should be suspected in younger women with interstitial lung disorders. Lymphangioleiomyomatosis can be diagnosed by a biopsy or an elevated serum vascular endothelial growth factor D (VEGF-D).[26]

All patients newly diagnosed with lymphangioleiomyomatosis should receive renal imaging as screening for angiomyolipomas. However, due to its rarity, routine VEGF-D testing for lymphangioleiomyomatosis is not necessary or recommended for most female patients with angiomyolipomas but should be considered in younger women with multiple renal AMLs, especially if they also have pulmonary issues. (See our companion article on lymphangioleiomyomatosis.)[23]


Renal angiomyolipomas are rare kidney tumors that account for only 0.3 to 3% of all renal neoplasms.[2][27] The overall prevalence rate of renal angiomyolipomas ranges from 0.13 to 2.2%, with over eighty percent isolated and sporadic cases.[6][28][29][30] The other twenty percent develop in association with pulmonary lymphangioleiomyomatosis or tuberous sclerosis complex.[28][31] 

Renal angiomyolipomas tend to occur in females more than males, possibly due to estrogenic effects.[5] The size of the tumors also tends to be larger in females than males. There is an increased growth rate of angiomyolipomas in pregnant women and a higher risk of hemorrhagic complications.[32][33][34][35] Exogenous estrogen therapy also appears to increase the risk of bleeding from angiomyolipomas.[36]

At least 50 to 75% of patients with tuberous sclerosis will be found to have renal angiomyolipomas.[5][37][38][39] In these patients, the incidence of renal angiomyolipomas increases with age, while the initial presentation of the tumors tends to be younger (13 years vs. 24 years).


The exact reason for sporadic renal angiomyolipoma is not fully known.[5][28] It appears that all three tissue types are derived from pericytes (microcirculatory mural cells) as they all express pericyte markers except for the endothelial cell components that develop independently.[40][41]

Hereditary renal angiomyolipomas are caused by a mutation in either the TSC1 or TSC2 gene.[2][11] These two genes encode the essential proteins hamartin and tuberin, respectively.[3][5] The interaction between these two proteins forms a tumor suppressor complex.[5] This tumor suppressor complex inhibits the Mammalian Target of Rapamycin (mTOR) pathway, which is crucial for cell growth, angiogenesis, and protein synthesis.[5][28]

Deficient or defective TSC1 or TSC2 gene activity will lead to unchecked activation of the mTOR pathway resulting in the formation of angiomyolipomas.[5][16][42] 

Angiomyolipomas are generally considered benign and will only very rarely become malignant.[16] The majority of angiomyolipomas are asymptomatic and tend to remain stable in size. Only about 9% tend to enlarge over time.[43] Larger tumors (>6 cm) are more likely to enlarge and grow, hemorrhage, and cause symptoms.[43]


Renal angiomyolipomas can be classified histologically as either typical (triphasic) or atypical (monophasic or epithelioid).[3][44] Triphasic angiomyolipomas usually contain three tumor components (blood vessels or vascular, smooth muscle cells, and mature adipocytes). Monophasic angiomyolipomas usually consist of one major component, while other elements are typically present only in minimal amounts.[3][6][44]

Gross Pathology Descriptions

  • The mean tumor size is 6 cm, but the range varies from 0.5 to 25 cm.[3]
  • A "large" tumor would be >6 cm. (Historically, this was previously 4 cm.)
  • Circumscribed, not encapsulated.[45]
  • Tumors rarely have a cystic component.[44]
  • Tumors are usually unifocal and unilateral but could be bilateral or multiple, suggesting underlying tuberous sclerosis.[44]
  • The cut surface appearance could be gray-white (smooth muscle component), red (vascular component), or yellow (adipose component); the typical golden-yellow appearance depends on the fat content.[4]
  • It may or may not invade the local perinephric fat, lymphatics, or renal sinus.[3]
  • May rarely invade the renal vein and develop a tumor thrombus similar to malignant renal tumors with possible intracardiac extensions and pulmonary embolisms.[8][9]
  • Epitheliod variant tends to have minimal fat and may show metastasis in a third of cases.[46]

Microscopic Pathology Descriptions

  • The classic triphasic renal angiomyolipoma contains thick-walled dysmorphic, disorganized hyalinized blood vessels without elastic lamina.[47] 
  • The tumor also contains mature adipose tissue and myoid spindle cells.[45]
  • Epithelioid variant usually contains predominant polygonal cells with densely eosinophilic cytoplasm. Hemorrhage, necrosis, epithelioid cellular proliferation, and mitotic figures are typically common.[45][48]
  • In renal angiomyolipomas with epithelial cysts, the cysts are lined by cuboidal or hobnail epithelial cells.[45]


Renal angiomyolipomas are comprised of three cell types, all originating from pericytes.[5][40] The three cell types are atypical smooth-muscle-like, adipocyte-like, and epithelioid cells.[5] Accordingly, they express pericyte markers.[40][45] The expressed pericyte markers are angiotensin II type 1 receptor, platelet-derived growth factor receptor-beta, desmin, calponin, alpha-smooth muscle actin, and vascular endothelial growth factor receptor 2.[40] However, the endothelial cell or adipocyte markers, including CD31 and S-100, are not expressed.[40]

Renal angiomyolipomas typically stain strongly positive for estrogen, progesterone, and androgen receptors which partly explains the increased incidence in females and the accelerated growth in patients on hormonal therapy.

Melanocytic markers for spindle cells (HMB-45 and Melan-A) can help differentiate angiomyolipomas from various sarcomas.[16][48]

Malignant angiomyolipomas are extremely rare. Risk factors would include fat-invisible lesions on imaging, pure epithelioid histology, a size greater than 7 cm, and the presence of intralesional necrosis.[16][49][50]

History and Physical

Renal angiomyolipomas are mostly asymptomatic and typically diagnosed incidentally.[5] Advances in imaging technology have significantly increased the likelihood of diagnosing more cases.[44] 

Historically, up to 15% of patients would present with a spontaneous retroperitoneal hemorrhage (also called Wunderlich syndrome). This can be severe and lead to shock in about one-third of patients.[5] Therefore, the main clinical concern in a patient newly diagnosed with renal angiomyolipoma is the risk of potentially life-threatening bleeding.[5] (Spontaneous retroperitoneal bleeding can also be caused by renal cell cancers, nephritis, and polyarteritis nodosa, but angiomyolipomas are the most common etiology.)

Possible clinical signs and symptoms include flank pain, palpable abdominal mass, urinary tract infection, hematuria, anemia, severe renal insufficiency, and shock.[5][6] Classic renal angiomyolipomas have a benign prognosis, but the epithelioid variant can undergo malignant transformation.[16]

Renal angiomyolipomas associated with tuberous sclerosis complex or pulmonary lymphangioleiomyomatosis tend to be more aggressive, occur at an earlier age, are likelier to be bilateral and multifocal, and are larger at initial diagnosis than the more common sporadic variety.[4][5][51]


In clinical practice, angiomyolipomas appear as either fat-rich, fat-poor, or fat-invisible masses.[52] About 5% of angiomyolipomas will be of the fat-poor or fat-invisible variety.[53][54][55]

CT scanning is generally used first, often for unrelated reasons, and may be sufficient. If not, an MRI will be more sensitive in identifying fat-poor angiomyolipomas.[43][56] CT scans also have the advantages of wide availability, lower cost, easier access, and can be performed quickly. For fat-invisible lesions, no imaging study will suffice, and it will require either a percutaneous biopsy or surgical intervention.[43]

The cornerstone for identifying renal angiomyolipoma is diagnostic imaging. A  biopsy is not generally required to diagnose an angiomyolipoma but might be needed to exclude malignancy in difficult or complex cases such as fat-invisible renal mass lesions. Several imaging modalities help diagnose this condition as described below:

Ultrasonography: Hyperechoic lesion associated with a posterior acoustic shadowing is the typical feature of a fat-rich angiomyolipoma.[6] Renal masses might be iso or hyperechogenic, and a significant percentage (up to 30%) of smaller renal cell cancers can appear similarly.[5][6][57] 

The lesion's echogenicity directly correlates with the total fat content.[31] Fat-poor angiomyolipomas have a mixed echogenicity.[4][5] Fat-invisible angiomyolipomas are homogeneously isoechoic.[6] 

Unfortunately, about a third of renal cell carcinomas can demonstrate a similar appearance on ultrasound.[57] Accordingly, the ultrasonographic findings in angiomyolipomas are often inconclusive, and further investigations are still required.[5][6] Overall diagnostic accuracy of ultrasound in the initial diagnosis of angiomyolipomas is only about 78%.[58] 

The combination of tumor size with ultrasonic image-based quantitative textural analysis improves the ability of ultrasonography to differentiate hyperechoic renal cell carcinomas from angiomyolipomas with a higher degree of accuracy.[59]Ultrasonography can be most useful in tracking the progress of known lesions as it is cost-efficient and minimizes ionizing radiation exposure.[16][60]

A CT or MRI is suggested if the ultrasound shows significant growth (>2.5 mm/year) or a potentially serious change. (It is helpful to repeat the same imaging modality used to make the original diagnosis so the comparison can be more precise.) For these reasons, a baseline ultrasound is suggested for newly diagnosed angiomyolipomas if not already obtained. The combination of tumor size with ultrasound image-based quantitative textural analysis improves the ability of ultrasonography to differentiate hyperechoic renal cell carcinomas from angiomyolipomas with a higher degree of accuracy.[59]

Computed Tomography: The presence of a region of interest on CT scanning that contains attenuations of –10 Hounsfield Units or less is considered a dependable and reliable sign of fatty tissue, which is easily seen in most fat-rich angiomyolipomas.[5][6] The CT scan may not show a hypoattenuating area that measures less than –10 HU in fat-poor angiomyolipomas.[61] 

For this reason, proper placement of the region of interest (ROI) is essential to detect the fatty tissue component of suspicious renal masses. This is because the attenuation values will be higher if the ROI is placed on the muscular or vascular component than if placed on fatty tissue.[5][6] 

Fat-poor angiomyolipomas appear heterogeneously hyperattenuating or iso-attenuating. Fat-invisible angiomyolipomas appear homogenously hyperattenuating because there is insufficient adipose tissue to show any decreased density. In these cases, an MRI is usually the next recommended step. In selected cases, a contrast-enhanced CT scan may be indicated if there is a high suspicion of active bleeding, as it is necessary to find tortuous blood vessels prone to hemorrhage before a therapeutic embolization can be performed.[5][6][62]

Magnetic Resonance Imaging:  There is little difference in accuracy between MRI and CT scans for detecting most renal angiomyolipoma although MRI is considered superior in fat-poor lesions.[5][6][31] 

In one study of 98 pathologically confirmed fat-poor angiomyolipomas, 23% were identifiable on MRI but not CT scan.[63] The classical approach for diagnosing this condition is locating the fatty component inside the mass.[5] The best way to find the fatty area is by comparing the T1-weighted MRI images with and without selective fat suppression.[6]

Fat-rich angiomyolipomas show T1-hypointensity (dark) with fat suppression and T1-hyperintensity (bright) without fat suppression. It is important to note that this T1-hyperintensity is also present in other conditions like renal cell carcinomas and hemorrhagic cysts so it is not a specific, definitive, diagnostic manifestation of angiomyolipomas.[6][31] 

The main difficulty is to diagnose the fat-invisible mass, which contains too little fat to manifest the hypointensity on the fat-suppressed images required for making the diagnosis.

The application of MRI artifacts had been proposed for improved evaluation of the fat content in renal tumors. One of these is the India ink artifact which makes a black line at the boundary between fat and water. Applying this type of artifact helps diagnose small tumors and fat-poor angiomyolipomas—phase versus opposed phase chemical shift MRI assists in differentiating fat-poor angiomyolipomas and renal cell carcinomas. T2-weighted images are also beneficial for diagnosing renal angiomyolipomas.[5][6] 

Fat-rich angiomyolipomas are usually hyperintense while fat-poor angiomyolipomas manifest as heterogeneous or homogeneously hypointense in comparison to renal tissues.[5][16] Fat-invisible angiomyolipomas are homogenously hypointense compared to the renal parenchyma due to their minimal amount of fat.[62][64] 

Gadolinium contrast is generally not needed for diagnosis but can help identify internal aneurysms and determine general vascularity. Overall sensitivity and specificity of MRI for diagnosing fat-poor angiomyolipomas have been reported as 83% and 90%, respectively.[56] A biopsy may be necessary if a definitive diagnosis cannot be made by MRI imaging.

Percutaneous Biopsy: Percutaneous renal biopsies are mainly indicated to differentiate malignant renal lesions from benign masses.[5] As the vast majority of renal masses show characteristic signs of malignancy and benign lesions, such as angiomyolipomas, are usually diagnosed reliably with imaging, routine percutaneous biopsies are not generally required or recommended. Lesions that raise the suspicion of malignancy will typically demonstrate necrosis, intralesional calcifications, or lymphadenopathy; in these cases, it is reasonable to proceed directly to surgical resection.[17] 

The purpose of a percutaneous renal biopsy is mainly to identify benign lesions that would not require aggressive treatment in those rare equivocal cases where imaging modalities alone are unable to make a definitive diagnosis.[5][31][65]     

A percutaneous renal biopsy is typically only used to differentiate a renal cell carcinoma from a fat-invisible or low-fat angiomyolipoma if both MRI and CT scan images are inconclusive or indecisive.[5][66] On a CT scan, a fat-invisible angiomyolipoma usually manifests as a hyperattenuating lesion that enhances homogeneously.[5][63] 

Although this imaging presentation is unusual for a renal cell carcinoma, both lesions may look identical.[5][63] In this situation, the lesion should first be evaluated by MRI to get further information.[5][63] While fat-invisible angiomyolipomas appear hypointense homogenously on T2-weighted images on MRI, renal cell carcinomas (clear cell subtype) manifest as hyperintense lesions.[5][63] The main issue is the papillary renal cell carcinoma which also appears as a hypointense mass.[5][63] 

A percutaneous renal biopsy may be necessary to differentiate between the papillary subtype of renal cell carcinoma and fat-invisible angiomyolipomas if the lesion is small (considered as less than 3 cm) and appears T2-hypointense on MRI without any evidence of fat inside the tumor.[5][65] If there is a high possibility of bleeding or the mass is particularly large, proceeding directly to a suitable surgical treatment could be the best option to avoid hemorrhagic complications.[5][6] 

The risk of significant bleeding following a percutaneous biopsy in fat-invisible angiomyolipomas is no greater than for other renal masses.[67]

Renal nuclear scanning utilizing technetium-99m (Tc) mercaptoacetythiglycine (MAG3) renography is not generally used in the routine evaluation of angiomyolipomas and other renal masses. It evaluates relative renal function, which can be helpful before nephron-sparing surgery. It may also be useful in differentiating renal masses and pseudomasses in cases where other imaging modalities are ambiguous.

Evaluation Summary:

  • Ultrasonography can be useful for the initial detection of a renal mass or for tracking but is not reliable enough for an initial diagnosis.
  • CT scanning is generally used first in the initial evaluation of renal masses, usually for unrelated reasons, and is often sufficient for diagnosis.
  • CT scans also have the advantages of wider availability, lower cost, easier access, and can be performed quickly.
  • An MRI will be more sensitive in identifying fat-poor angiomyolipomas if the CT scan is inconclusive.[43][56] 
  • For fat-invisible lesions, no imaging study will suffice, and a definitive diagnosis will require either a percutaneous biopsy or direct surgical intervention.[43] 
  • If any of these means cannot determine a reliable diagnosis, the mass lesion should be treated as a renal malignancy.

Treatment / Management

Indications for Treatment

Most angiomyolipoma cases are asymptomatic and usually do not require treatment, but therapeutic interventions are required in the minority of cases.[5] 

In the past, the main indications for intervention were the presence of the symptoms, suspicion of malignancy, the presence of the tumor in women of childbearing age, and a size larger than 4 cm.[5] 

Recently, the historical 4 cm size threshold has been questioned. Some recent studies do not support the 4 cm size criterion because only 30% of renal angiomyolipomas larger than 4 cm were symptomatic.[5] 

Other studies revealed that using the 4 cm criterion as a predictor of hemorrhage has lower specificity than the tumoral aneurysm size of 5 mm.[5][31] The degree and complexity of the lesion's vascularity (multiple, large, tortuous vessels, aneurysms) is a better general indicator of the need to require an intervention to prevent significant bleeding.[31] 

This evidence suggests that the vascularity of the angiomyolipoma and the size of any related aneurysms are ultimately more significant than the tumor size alone.[31] Increasing the size criteria to >6 cm avoided presumed overtreatment in 65% of patients.[68]

Angiomyolipomas can be especially troubling during a pregnancy given the high levels of estrogen receptors in these lesions, which causes them to enlarge, and the relatively high rate of reported hemorrhage.[69][70][71] 

The European Association of Urology and the Canadian Best Practice Report recommend that the treatment of angiomyolipomas be considered and discussed with women of reproductive age who have been found to have these lesions.[72][73][69]

If an angiomyolipoma is found in a pregnant lady, it should be managed similarly to other renal tumors, and the treatment should be highly individualized.[74]

Currently, the European Association of Urology and the Canadian Urological Association recommend that intervention is required in well-selected cases and should consider the following criteria:[72][73][13]

  • Symptoms from the tumor(s) such as persistent pain
  • Large lesions (>6 cm, formerly >4 cm)
  • Multiple lesions
  • Lesions that are enlarging >2.5 mm per year (>5 mm yearly is considered high risk)
  • Intralesional aneurysms >5 mm
  • Poor access to emergency care or follow-up
  • Poor patient compliance 
  • Presence of a tumor in women of childbearing age 
  • High-risk occupations such as commercial airline pilots
  • Female patients who must continue hormonal therapy

Possible interventions include medical treatment with mTOR inhibitors, thermal ablation (radiofrequency ablation and cryotherapy), selective renal artery embolization, and surgical excision (total nephrectomy, partial nephron-sparing surgery).[5]

Medical Treatment: Hereditary renal angiomyolipomas (those associated with tuberous sclerosis and/or pulmonary lymphangioleiomyomatosis) are caused by a mutation in the TSC1 or TSC2 genes resulting in unchecked activation of the mTOR pathway. This results in cell overgrowth and the formation of angiomyolipomas.[11][12] 

Medications that inhibit the mTOR pathway can interrupt tumor progression and promote the reversion of the existing lesions.[5][12] It has been suggested that all hereditary angiomyolipoma lesions >3 cm be treated with mTOR inhibitor medications even if asymptomatic.[1][5]

Sirolimus was the first mTOR inhibitor used to treat hereditary angiomyolipomas.[75] Initial studies with sirolimus showed a greater volume reduction in fat-poor compared to fat-rich angiomyolipomas. This was most obvious in the more highly vascularized and low-fat areas of the tumor. Excessive tumoral vascularity and related aneurysms were markedly reduced by 75% to 100%.[76]

Everolimus (also an mTOR inhibitor) was approved by the U.S Food and Drug Administration (FDA) for treating hereditary angiomyolipomas in the setting of tuberous sclerosis complex.[5][16][28][77][78] An average 55% reduction in tumor size has been reported with everolimus.[79] The standard starting dose is 10 mg daily.

The use of everolimus in sporadic angiomyolipomas is more problematic. A 2020 phase II multi-institutional prospective trial reported good efficacy in patients who were given 4 to 6 cycles of monthly everolimus therapy based on response and tolerability. Over 50% of the patients demonstrated a reduction in tumor size of 25% or more, but almost 50% developed side effects or toxicities that required modification or discontinuation of therapy.[80] This compares favorably with the EXIST-2 trial of everolimus use in hereditary angiomyolipomas.[81]

It is important to recognize that mTOR inhibitors are not risk-free and have many reported side effects.[14] Dose adjustment or even drug discontinuation may be required if the patient manifests any severe side effects.[82] The following encompasses the most likely side effects associated with these medications:[14]

  • Amenorrhea
  • Delayed wound healing
  • Dyslipidemia
  • Fatigue
  • Hyperglycemia
  • Hypophosphatemia
  • Infections
  • Lymphopenia
  • Microcytic anemia
  • Non-infectious pneumonitis
  • Proteinuria
  • Stomatitis
  • Thrombocytopenia

Thermal Ablation

Thermal ablative therapy (radiofrequency ablation, cryotherapy, etc.) has been recommended by the American Urological Association Guidelines for small renal masses (<3 cm).[83] 

Specific selection depends on patient characteristics, tumor size, and specific location, as well as local experience and expertise. Thermal ablative therapy has the advantage of being able to perform simultaneous percutaneous renal biopsies and being effective regardless of the underlying nature of the tumor. This gives them a significant advantage over selective angiographic embolization, where the diagnosis has to be clear and definitive before treatment, although embolization remains the preferred minimally invasive procedure for angiomyolipomas. The most commonly used thermal ablative modalities include cryotherapy and radiofrequency ablation.

  • Cryotherapy has been used very successfully in small numbers of angiomyolipoma patients, but there is insufficiently reported data to recommend its routine use.[31][83][84][85] 
    • Cryotherapy has some unique advantages, which include minimal damage to surrounding renal tissue, a well-defined area of ablation, the ability to obtain a tissue biopsy during the same procedure, percutaneous accessibility, minimally invasive technology, and the delivery of definitive treatment to the mass regardless if it is eventually determined to be a benign or malignant lesion.
    • In institutions that have experience with this modality, cryotherapy may be a very reasonable option, especially where arterial embolization has failed or is not technically feasible, as well as in situations where the absolute minimal loss of renal function is desired or there is some remaining doubt about the diagnosis. This would also include patients with pre-existing renal failure or extensive bilateral disease as an alternative to surgical resection.
    • If renal cryoablation of the tumor is being considered, it would be best to include it within a clinical trial if possible. No data is yet available on the possible combination of angiographic embolization together with renal cryotherapy, but it might theoretically provide superior results for larger tumors.
  • Radiofrequency ablation of angiomyolipomas has demonstrated minimal complications with good efficacy. This minimally invasive technique is most suitable for small-sized tumors which are asymptomatic but could also target large masses.[5][31] 
    • Radiofrequency ablation targets the vascular and solid elements of the tumor mass without damaging normal renal tissue. The efficacy of radiofrequency ablation for renal angiomyolipomas has been assessed for small angiomyolipomas in relatively small series.[5] 
    • In one study, 15 small renal angiomyolipomas were treated successfully with complete disappearance of tumoral enhancement on CT scan and a low complication rate (13.3%) at a mean follow-up of 21 months.[86] 
    • Another study reported a reduction in tumor size from 4.5 cm to 2.9 cm after radiofrequency ablation of a sporadic angiomyolipoma in a patient with a solitary kidney without any complications or tumor recurrence at the 12-month follow-up.[87][88] 
    • Four large angiomyolipomas were treated by radiofrequency ablation in another study, and no complications or hemorrhagic events were reported. This study also showed, during a follow-up of 48 months, a significant decrease in the mean soft-tissue-to-total tumor ratio, but the total tumor volume did not significantly change.[88][89] CT scans usually guide the procedure, but ultrasonography is a possible alternative.[5] 
    • CT scan guidance is required for tumors that cannot be easily and safely targeted by ultrasonography. Superselective renal artery embolization combined with radiofrequency ablation has produced excellent success rates in a small number of studies.[90] Further studies are needed to determine if this is superior long-term to alternative treatment.

Selective Renal Artery Embolization: In the past, the main treatment for angiomyolipoma was surgical excision because tumor malignancy could not be excluded.[3][16] Currently, selective transarterial embolization is considered the first-line treatment, especially if there is a risk of acute bleeding, active hemorrhaging, or hemodynamic instability.[5][14][31][72][91] 

Selective renal artery embolization is the preferred procedural option reserving surgery and possibly thermal ablative therapies for patients with vascular malformations, uncontrollable symptoms, embolization failures, or diagnostic uncertainty.[5][14] The overall success rate of selective renal artery embolization is 93%, with an average reduction in tumor size of 38%.[5][14]

When the surgical option is indicated, preoperative embolization of the tumor may be considered to reduce the complications and the difficulty of the operation.[4][5][31] Embolization is not a risk-free option, and it is associated with a relatively high rate of side effects (42.8%).[5] 

Most of these side effects are related to a post-embolization syndrome characterized by flank pain, fever, vomiting, nausea, and leucocytosis during the first three days after the procedure.[5][16] 

These side effects are generally managed conservatively with standard supportive care. Prescribing antipyretics, antiemetics, and analgesia prophylactically could play a major role in minimizing and controlling these symptoms.[5][16][72] Thirty percent of cases treated with selective arterial embolization will need a second treatment due primarily to tumor revascularization.[14][73]

Surgical Excision: Total or partial nephrectomy is the only treatment option that totally eradicates the entire renal mass.[3] Every surgical operation should use a nephron-sparing approach whenever possible.[3][14] 

Parenchymal preservation is especially important in patients with hereditary angiomyolipomas because of the higher recurrence rate, faster growth rate, and multifocal disease pattern.[5] 

Nephrectomy is usually indicated when the suspicion of malignancy is high and the renal mass is particularly large or when other treatment modalities cannot be performed.[5] However, in an emergency, a nephrectomy can be a lifesaving option.[5][11][92] 

Surgical excision has the advantage of a higher cure rate and the need for fewer follow-up procedures with reduced surveillance compared with arterial embolization.

Active Surveillance and Follow-up

Generally, active surveillance is used to monitor the ongoing progression of known tumors and the development of new ones when the diagnostic evaluations are completed and the indications for treatment are not present.[5][43] The overall rate of spontaneous bleeding from angiomyolipomas is only 2%, so surveillance in most cases is reasonable.[73]

There are currently no definitive guidelines for sporadic angiomyolipomas regarding the frequency of imaging studies or which imaging modality should be used for that reason.[5][31] The decisions should be guided according to the individual clinical scenario and history.[31][93] 

An annual repeat of imaging may be appropriate for small and solitary lesions.[6] Biannual (twice annual) imaging is generally recommended at least initially for hereditary tumors (associated with tuberous sclerosis or lymphangioleiomyomatosis), multiple, bilateral, and larger lesions, as some have been found to grow up to 1.5 cm a year.[43][94]

For hereditary angiomyolipomas, the International Tuberous Sclerosis Complex Consensus highly recommends using the MRI yearly to monitor the condition because of its higher sensitivity in detecting adipose tissue.[5] Most published protocols start with biannual imaging. If there is little change, this is then modified to annual screenings.[43] It is also highly recommended to check the blood pressure and renal function in these cases annually.[5] 

Ultrasound is usually sufficient for monitoring with a CT scan or MRI if significant changes are found. With long-term follow-up, it is reasonable to avoid routine CT scanning to minimize radiation exposure.

Treatment Summary

  • Most angiomyolipomas do not need any treatment.
  • The need for treatment is based on current symptoms, size (>6 cm), growth >2.5 mm/yr, intratumoral aneurysms >5 mm, high-risk situations, and potential lack of access to healthcare.
  • The least invasive treatment modality should be used whenever possible, which minimizes complications and loss of renal function.
  • Everolimus has shown efficacy in controlling tumor growth and promoting shrinkage in hereditary angiomyolipomas. Its use in the more common sporadic angiomyolipomas is uncertain, but early studies suggest it can be effective. 
  • Thermal therapies such as radiofrequency ablation and cryotherapy allow percutaneous biopsies to be performed simultaneously and will be effective for both benign and malignant lesions. They should certainly be considered for smaller tumors (<3 cm) depending on local experience, expertise, and availability.
  • Selective angiographic embolization is the treatment of choice for active bleeding and prophylaxis of high-risk angiomyolipomas. However, there is a high retreatment rate of 30%, and it requires a definitive diagnosis before treatment.
  • Surgery is the most definitive, curative therapy reserved for situations that cannot be better managed with less invasive modalities. Nephron-sparing techniques are recommended.

Differential Diagnosis

It is essential to know that renal angiomyolipoma has different types ( fat-rich angiomyolipoma, fat-poor angiomyolipoma, and fat-invisible angiomyolipoma).[31] Fat-rich angiomyolipomas are diagnosed easily on imaging due to the high amount of adipose tissue inside the mass.[5] The main issue is correctly diagnosing other angiomyolipomas where fat visualization is poor or invisible.[5] 

It is necessary to exclude the other differential diagnoses before deciding on treatment.[5] The possible differential diagnoses of renal angiomyolipoma are listed below [95][96]

  • Renal cell carcinoma 
  • Oncocytoma
  • Wilms tumor
  • Retroperitoneal liposarcoma
  • Adrenal myelolipoma
  • Tumors metastatic to the kidney

The recent high use of high-resolution imaging modalities has raised the detection of small renal masses. Many of these small renal lesions are found incidentally, are assumed to be possible renal cell carcinomas, and are managed accordingly.[5] About 21.5 percent of those renal masses are ultimately diagnosed as benign lesions after surgical removal, and renal angiomyolipomas account for about half of these.[5] 

Differentiating renal cell carcinomas from angiomyolipomas can sometimes be challenging in routine clinical practice.[61][97][98] Apart from the classic angiomyolipoma, which could be featured from renal cell carcinoma by detecting a sufficient amount of fat on a CT scan, the main issue is differentiating the fat-poor or fat invisible angiomyolipoma from renal cell carcinoma.[5] 

Clinical information that favors the diagnosis of angiomyolipoma includes female gender, younger age, and asymptomatic clinical manifestations.[5] Imaging results that increase the possibility of angiomyolipoma include multiple lesions, no calcifications, T2-weighted hypointensity on MRI, and hyperattenuation on CT scan.[5] However, because these features do not necessarily exist in every case and there are many exceptions, no solitary clinical finding or imaging modality is perfect in all cases.[5][99][100][101]

Retroperitoneal liposarcomas may also appear similar to larger angiomyolipomas. Since angiomyolipomas are renal parenchymal tumors, there will be an indentation or dimple where the mass originated, while a liposarcoma will tend to envelop and compress the entire kidney with no specific originating marker.[102][103]

When a renal mass lesion cannot be reliably determined to be an angiomyolipoma from imaging alone but is considered suspicious for AML, a percutaneous biopsy is reasonable, especially for high-risk patients, as it will avoid the risks and potential complications of surgery.[66] 

If there are indications of malignancy (such as internal necrosis, calcifications, or local lymphadenopathy), it should be treated as a malignancy unless proven benign by percutaneous renal biopsy.[5][6][66] If the diagnosis remains uncertain, the lesion should be treated as a malignancy.

Lesions suspicious of possible malignancy (tumoral necrosis or calcifications, regional lymphadenopathy, metastasis, perinephric extension) should generally be treated surgically.[17]


Small angiomyolipomas and those without aneurysms usually have a good prognosis as the risk of spontaneous bleeding are low, at only 2%.[5][73]  Renal angiomyolipomas that contain aneurysms >5 mm or the size of the tumor is larger than 6 cm pose a significant risk of spontaneous rupture and bleeding, which is considered a life-threatening condition.[16][104] 

Another important prognostic factor is the malignant potential, as some types of angiomyolipoma have a greater tendency for this transformation.[5]  

There is a need for updated clinical guidelines to help guide physicians to optimal management in each of these rare and unusual cases. Improved treatments or even a potential cure will require ongoing translational research in genomics, immunotherapy, and other new treatment technologies.[105]


Renal angiomyolipoma is a rare benign neoplasm, but it may still impose significant morbidity and mortality due to the tumor's unique vascular characteristics and the possible complications associated with treatment.[5]

The risk of bleeding associated with renal angiomyolipomas is a challenging factor in saving the patient's life while preserving renal function.[5] Several studies have documented that large tumors (more than 6 cm) and tuberous sclerosis complex-associated lesions are considered more susceptible to bleeding than small sporadic lesions, raising the need for prophylactic treatment.[16] 

Another important complication includes the need for long-term surveillance and the potential for renal impairment over time associated with renal angiomyolipomas.[11]


The management of renal angiomyolipoma and its complications requires a multidisciplinary team.[5] This team can consist of the following specialties:

  • Nephrologist
  • Radiologist
  • Interventional radiologist
  • Oncologist
  • Urologist
  • Pathologist 
  • Clinical pathologist
  • Vascular surgeon
  • General surgeon
  • Genetics counselor
  • Primary care

Deterrence and Patient Education

Patients with renal angiomyolipoma should be informed about this disease's benign nature.[5] Health professionals should clarify that available medications and minimally invasive treatments can stop the disease's progression and lower the spontaneous bleeding risk.[5] 

Health care providers also have to advise the patients about the importance of medication adherence and compliance and the need for long-term surveillance.[16] 

Any woman of childbearing age diagnosed with renal angiomyolipoma who plans to become pregnant should seek consultation to discuss the management of her condition before and during the pregnancy. Pregnancy is considered a significant risk factor for disease progression and complications as the tumor mass will likely grow and may rupture while she is carrying.[5][11]

Pearls and Other Issues

  • Over 90% of all angiomyolipomas never need treatment.
  • A number of experts recommend an evaluation of all patients with newly diagnosed angiomyolipomas for tuberous sclerosis.
  • Conversely, all patients with tuberous sclerosis should be screened for angiomyolipomas.
  • All patients with lymphangioleiomyomatosis should receive renal imaging for angiomyolipomas.
  • Asymptomatic patients with <2 lesions smaller than 4 cm are unlikely to have tuberous sclerosis.
  • Consider a biopsy if the diagnosis cannot be reliably made from CT and MRI scanning alone.
  • If the diagnosis is still in doubt, treat the lesion as a malignancy.
  • Ultrasound is not sufficiently detailed to make a definitive diagnosis but can track previously diagnosed lesions.
  • The risk of a percutaneous biopsy is no greater for patients with low-fat or invisible-fat angiomyolipomas than for other renal tumors.
  • MRI imaging is more sensitive in detecting fat than CT and is, therefore, most useful for fat-poor lesions. (No imaging will show a fat-invisible lesion.)
  • If all measures have failed to confirm a diagnosis reliably, treating the lesion as malignant is recommended.
  • Active bleeding is best controlled with selective angiographic embolization, but there is a 30% retreatment rate.
  • Surgical intervention with minimally invasive ablative techniques should be considered when possible.
  • Women of childbearing age should consider prophylactic treatment of angiomyolipomas due to the high risk of complications during pregnancy.

Enhancing Healthcare Team Outcomes

Managing renal angiomyolipoma requires the collaboration of the entire interprofessional healthcare team.[16] The primary healthcare provider should be aware of this disease, especially if the patient presents with flank pain and palpable abdominal mass.[5] 

The role of the radiologist and interventional radiologist is crucial to confirm the diagnosis and monitor the disease progression through imaging.[5] Few cases require a percutaneous renal biopsy to confirm the diagnosis if the imaging modalities cannot confirm it.[31] 

All medical efforts should focus on preserving renal function while preventing disease progression and associated complications.[5][11] Other specialists, as detailed above, may be called in to consult on the case.

The nursing staff plays a crucial role in patient counseling, assisting in surgery, coordinating contacts and interventions between specialties, and answering patient questions. If medical therapy is part of the treatment plan, the pharmacist will counsel the patient on proper dosing and administration and perform medication reconciliation, contacting the ordering or prescribing clinician if any problems are noted.

All interprofessional team members must provide meticulous documentation of their activities and interventions in the patient's medical record so all team members have access to the same up-to-date, accurate information. All interprofessional team members should likewise be able to engage in open communication regarding the case with all other team members so the best therapeutic options can be implemented. This interprofessional approach will drive optimal patient outcomes. [Level 5]

(Click Image to Enlarge)
Contributed by D. Kabir MD


8/8/2023 1:51:50 AM



Hatano T, Egawa S. Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care. Asian journal of surgery. 2020 Oct:43(10):967-972. doi: 10.1016/j.asjsur.2019.12.008. Epub 2020 Jan 17     [PubMed PMID: 31959574]


Al-Thani H, El-Menyar A, Al-Sulaiti M, El-Mabrok J, Hajaji K, Elgohary H, Al-Malki A, Tabeb A. Clinical presentation, management, and outcome of patients with incidental renal angiomyolipoma in qatar. Oman medical journal. 2014 Nov:29(6):419-24. doi: 10.5001/omj.2014.112. Epub     [PubMed PMID: 25584159]


Lane BR, Aydin H, Danforth TL, Zhou M, Remer EM, Novick AC, Campbell SC. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. The Journal of urology. 2008 Sep:180(3):836-43. doi: 10.1016/j.juro.2008.05.041. Epub 2008 Jul 16     [PubMed PMID: 18635231]


Halpenny D, Snow A, McNeill G, Torreggiani WC. The radiological diagnosis and treatment of renal angiomyolipoma-current status. Clinical radiology. 2010 Feb:65(2):99-108. doi: 10.1016/j.crad.2009.09.014. Epub 2009 Dec 3     [PubMed PMID: 20103431]


Vos N, Oyen R. Renal Angiomyolipoma: The Good, the Bad, and the Ugly. Journal of the Belgian Society of Radiology. 2018 Apr 20:102(1):41. doi: 10.5334/jbsr.1536. Epub 2018 Apr 20     [PubMed PMID: 30039053]


Jinzaki M, Silverman SG, Akita H, Nagashima Y, Mikami S, Oya M. Renal angiomyolipoma: a radiological classification and update on recent developments in diagnosis and management. Abdominal imaging. 2014 Jun:39(3):588-604. doi: 10.1007/s00261-014-0083-3. Epub     [PubMed PMID: 24504542]


Minja EJ, Pellerin M, Saviano N, Chamberlain RS. Retroperitoneal extrarenal angiomyolipomas: an evidence-based approach to a rare clinical entity. Case reports in nephrology. 2012:2012():374107. doi: 10.1155/2012/374107. Epub 2012 Jul 12     [PubMed PMID: 24555133]

Level 3 (low-level) evidence


Wang D, Liu M, Li Y, Xie M. Right renal angiomyolipoma with intracardiac extension and pulmonary embolism. Journal of clinical ultrasound : JCU. 2021 Jun:49(5):516-519. doi: 10.1002/jcu.22968. Epub 2020 Dec 15     [PubMed PMID: 33325037]


Bouaziz H, Ghalleb M, Tounsi N, Riahi N, Bouzaiene H, Ziadi J, Hassouna JB, Slimane M, Rahal K. A renal angiomyolipoma with a challenging presentation: a case report. Journal of medical case reports. 2021 Sep 27:15(1):477. doi: 10.1186/s13256-021-03073-0. Epub 2021 Sep 27     [PubMed PMID: 34565446]

Level 3 (low-level) evidence


Zhan R, Li YQ, Chen CY, Hu HY, Zhang C. Primary kidney malignant epithelioid angiomyolipoma: Two cases report and review of literature. Medicine. 2018 Aug:97(32):e11805. doi: 10.1097/MD.0000000000011805. Epub     [PubMed PMID: 30095646]

Level 3 (low-level) evidence


Seyam RM, Alkhudair WK, Kattan SA, Alotaibi MF, Alzahrani HM, Altaweel WM. The Risks of Renal Angiomyolipoma: Reviewing the Evidence. Journal of kidney cancer and VHL. 2017:4(4):13-25. doi: 10.15586/jkcvhl.2017.97. Epub 2017 Oct 16     [PubMed PMID: 29090118]


Wang W, Guo G, Shi G, Wei X, Hu Z, Li H, Zhang X, Ye D, Zhang Y. A Multi-Centric Study Assessing Safety and Efficacy of Everolimus in Adult Chinese Patients With Tuberous Sclerosis Complex Associated Renal Angiomyolipomas. Frontiers in oncology. 2022:12():871723. doi: 10.3389/fonc.2022.871723. Epub 2022 Jul 4     [PubMed PMID: 35860575]


Bhatt JR, Richard PO, Kim NS, Finelli A, Manickavachagam K, Legere L, Evans A, Pei Y, Sykes J, Jhaveri K, Jewett MAS. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs }4cm Can Be Offered Active Surveillance as an Initial Management Strategy. European urology. 2016 Jul:70(1):85-90. doi: 10.1016/j.eururo.2016.01.048. Epub 2016 Feb 9     [PubMed PMID: 26873836]


Ariceta G, Buj MJ, Furlano M, Martínez V, Matamala A, Morales M, Robles NR, Sans L, Villacampa F, Torra R. Recommendations for the management of renal involvement in the tuberous sclerosis complex. Nefrologia. 2020 Mar-Apr:40(2):142-151. doi: 10.1016/j.nefro.2019.07.002. Epub 2019 Nov 10     [PubMed PMID: 31722796]


Zamora EA, Aeddula NR. Tuberous Sclerosis. StatPearls. 2024 Jan:():     [PubMed PMID: 30860727]


Flum AS, Hamoui N, Said MA, Yang XJ, Casalino DD, McGuire BB, Perry KT, Nadler RB. Update on the Diagnosis and Management of Renal Angiomyolipoma. The Journal of urology. 2016 Apr:195(4 Pt 1):834-46. doi: 10.1016/j.juro.2015.07.126. Epub 2015 Nov 21     [PubMed PMID: 26612197]


Sooriakumaran P, Gibbs P, Coughlin G, Attard V, Elmslie F, Kingswood C, Taylor J, Corbishley C, Patel U, Anderson C. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU international. 2010 Jan:105(1):101-6. doi: 10.1111/j.1464-410X.2009.08649.x. Epub 2009 Jun 2     [PubMed PMID: 19493268]

Level 3 (low-level) evidence


Seyam RM, Bissada NK, Kattan SA, Mokhtar AA, Aslam M, Fahmy WE, Mourad WA, Binmahfouz AA, Alzahrani HM, Hanash KA. Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms. Urology. 2008 Nov:72(5):1077-82. doi: 10.1016/j.urology.2008.07.049. Epub 2008 Sep 21     [PubMed PMID: 18805573]


Aydin H, Magi-Galluzzi C, Lane BR, Sercia L, Lopez JI, Rini BI, Zhou M. Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. The American journal of surgical pathology. 2009 Feb:33(2):289-97. doi: 10.1097/PAS.0b013e31817ed7a6. Epub     [PubMed PMID: 18852677]

Level 3 (low-level) evidence


Curatolo P, Bombardieri R. Tuberous sclerosis. Handbook of clinical neurology. 2008:87():129-51. doi: 10.1016/S0072-9752(07)87009-6. Epub     [PubMed PMID: 18809023]


Franz DN. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert review of anticancer therapy. 2011 Aug:11(8):1181-92. doi: 10.1586/era.11.93. Epub     [PubMed PMID: 21916571]


Harknett EC, Chang WY, Byrnes S, Johnson J, Lazor R, Cohen MM, Gray B, Geiling S, Telford H, Tattersfield AE, Hubbard RB, Johnson SR. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM : monthly journal of the Association of Physicians. 2011 Nov:104(11):971-9. doi: 10.1093/qjmed/hcr116. Epub 2011 Jul 15     [PubMed PMID: 21764810]


Khaddour K, Sankari A, Shayuk M. Lymphangioleiomyomatosis. StatPearls. 2024 Jan:():     [PubMed PMID: 30480964]


Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR, Raffin TA, Peavy HH, McCarthy K, Taveira-Dasilva A, McCormack FX, Avila NA, Decastro RM, Jacobs SS, Stylianou M, Fanburg BL, NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. American journal of respiratory and critical care medicine. 2006 Jan 1:173(1):105-11     [PubMed PMID: 16210669]


Bernstein SM, Newell JD Jr, Adamczyk D, Mortenson RL, King TE Jr, Lynch DA. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? American journal of respiratory and critical care medicine. 1995 Dec:152(6 Pt 1):2138-43     [PubMed PMID: 8520787]


McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D'Armiento JM, Inoue Y, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J, ATS/JRS Committee on Lymphangioleiomyomatosis. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. American journal of respiratory and critical care medicine. 2016 Sep 15:194(6):748-61. doi: 10.1164/rccm.201607-1384ST. Epub     [PubMed PMID: 27628078]

Level 1 (high-level) evidence


Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. The Journal of urology. 2002 Oct:168(4 Pt 1):1315-25     [PubMed PMID: 12352384]


Bissler JJ, Kingswood JC. Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review. Therapeutic advances in urology. 2016 Aug:8(4):279-290     [PubMed PMID: 27928430]

Level 3 (low-level) evidence


Fujii Y, Ajima J, Oka K, Tosaka A, Takehara Y. Benign renal tumors detected among healthy adults by abdominal ultrasonography. European urology. 1995:27(2):124-7     [PubMed PMID: 7744154]


Rule AD, Sasiwimonphan K, Lieske JC, Keddis MT, Torres VE, Vrtiska TJ. Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2012 May:59(5):611-8. doi: 10.1053/j.ajkd.2011.12.022. Epub 2012 Mar 6     [PubMed PMID: 22398108]


Kiefer RM, Stavropoulos SW. The Role of Interventional Radiology Techniques in the Management of Renal Angiomyolipomas. Current urology reports. 2017 May:18(5):36. doi: 10.1007/s11934-017-0687-6. Epub     [PubMed PMID: 28299630]


Lewis EL, Palmer JM. Renal angiomyolipoma and massive retroperitoneal hemorrhage during pregnancy. The Western journal of medicine. 1985 Nov:143(5):675-6     [PubMed PMID: 4082575]


Petrikovsky BM, Vintzileos AM, Cassidy SB, Egan JF. Tuberous sclerosis in pregnancy. American journal of perinatology. 1990 Apr:7(2):133-5     [PubMed PMID: 2184812]


Raft J, Lalot JM, Meistelman C, Longrois D. [Renal angiomyolipoma rupture during pregnancy]. Gynecologie, obstetrique & fertilite. 2006 Oct:34(10):917-9     [PubMed PMID: 16996772]


Zapardiel I, Delafuente-Valero J, Bajo-Arenas JM. Renal angiomyolipoma during pregnancy: review of the literature. Gynecologic and obstetric investigation. 2011:72(4):217-9. doi: 10.1159/000329328. Epub 2011 Aug 27     [PubMed PMID: 21876331]


Gould Rothberg BE, Grooms MC, Dharnidharka VR. Rapid growth of a kidney angiomyolipoma after initiation of oral contraceptive therapy. Obstetrics and gynecology. 2006 Sep:108(3 Pt 2):734-6     [PubMed PMID: 17018483]


Kingswood JC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D' Amato L, d'Augères GB, de Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, Nabbout R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen AC. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2019 Mar 1:34(3):502-508. doi: 10.1093/ndt/gfy063. Epub     [PubMed PMID: 29697822]

Level 2 (mid-level) evidence


Bachour K, House AA, Andrade DM, Connolly M, Debicki DB, Desbiens R, Fantaneanu TA, Kyriakopoulos P, Lattouf JB, Suller-Marti A, Marques PT, Keezer MR. Adults with tuberous sclerosis complex: A distinct patient population. Epilepsia. 2022 Mar:63(3):663-671. doi: 10.1111/epi.17159. Epub 2021 Dec 29     [PubMed PMID: 34967000]


Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES. Renal lesion growth in children with tuberous sclerosis complex. The Journal of urology. 1998 Jul:160(1):141-5     [PubMed PMID: 9628635]


Siroky BJ, Yin H, Dixon BP, Reichert RJ, Hellmann AR, Ramkumar T, Tsuchihashi Z, Bunni M, Dillon J, Bell PD, Sampson JR, Bissler JJ. Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy. American journal of physiology. Renal physiology. 2014 Sep 1:307(5):F560-70. doi: 10.1152/ajprenal.00569.2013. Epub 2014 Jun 11     [PubMed PMID: 24920756]


Karbowniczek M, Yu J, Henske EP. Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. The American journal of pathology. 2003 Feb:162(2):491-500     [PubMed PMID: 12547707]


von Ranke FM, Faria IM, Zanetti G, Hochhegger B, Souza AS Jr, Marchiori E. Imaging of tuberous sclerosis complex: a pictorial review. Radiologia brasileira. 2017 Jan-Feb:50(1):48-54. doi: 10.1590/0100-3984.2016.0020. Epub     [PubMed PMID: 28298732]


Guo Y, Kapoor A, Cheon P, So AI, Lattouf JB, Jamal M. Canadian Urological Association best practice report: Diagnosis and management of sporadic angiomyolipomas. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2020 Nov:14(11):E527-E536. doi: 10.5489/cuaj.6942. Epub     [PubMed PMID: 33213697]


Jinzaki M, Silverman SG, Akita H, Mikami S, Oya M. Diagnosis of Renal Angiomyolipomas: Classic, Fat-Poor, and Epithelioid Types. Seminars in ultrasound, CT, and MR. 2017 Feb:38(1):37-46. doi: 10.1053/j.sult.2016.11.001. Epub 2016 Nov 5     [PubMed PMID: 28237279]


Martignoni G, Pea M, Rocca PC, Bonetti F. Renal pathology in the tuberous sclerosis complex. Pathology. 2003 Dec:35(6):505-12     [PubMed PMID: 14660101]


Brimo F, Robinson B, Guo C, Zhou M, Latour M, Epstein JI. Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. The American journal of surgical pathology. 2010 May:34(5):715-22. doi: 10.1097/PAS.0b013e3181d90370. Epub     [PubMed PMID: 20410812]

Level 3 (low-level) evidence


Tamboli P, Ro JY, Amin MB, Ligato S, Ayala AG. Benign tumors and tumor-like lesions of the adult kidney. Part II: Benign mesenchymal and mixed neoplasms, and tumor-like lesions. Advances in anatomic pathology. 2000 Jan:7(1):47-66     [PubMed PMID: 10640201]

Level 3 (low-level) evidence


Eble JN, Amin MB, Young RH. Epithelioid angiomyolipoma of the kidney: a report of five cases with a prominent and diagnostically confusing epithelioid smooth muscle component. The American journal of surgical pathology. 1997 Oct:21(10):1123-30     [PubMed PMID: 9331283]

Level 3 (low-level) evidence


Christiano AP, Yang X, Gerber GS. Malignant transformation of renal angiomyolipoma. The Journal of urology. 1999 Jun:161(6):1900-1     [PubMed PMID: 10332463]


Nese N, Martignoni G, Fletcher CD, Gupta R, Pan CC, Kim H, Ro JY, Hwang IS, Sato K, Bonetti F, Pea M, Amin MB, Hes O, Svec A, Kida M, Vankalakunti M, Berel D, Rogatko A, Gown AM, Amin MB. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. The American journal of surgical pathology. 2011 Feb:35(2):161-76. doi: 10.1097/PAS.0b013e318206f2a9. Epub     [PubMed PMID: 21263237]

Level 3 (low-level) evidence


Logue LG, Acker RE, Sienko AE. Best cases from the AFIP: angiomyolipomas in tuberous sclerosis. Radiographics : a review publication of the Radiological Society of North America, Inc. 2003 Jan-Feb:23(1):241-6     [PubMed PMID: 12533658]

Level 3 (low-level) evidence


Park BK. Renal Angiomyolipoma: Radiologic Classification and Imaging Features According to the Amount of Fat. AJR. American journal of roentgenology. 2017 Oct:209(4):826-835. doi: 10.2214/AJR.17.17973. Epub 2017 Jul 20     [PubMed PMID: 28726505]


Schieda N, Kielar AZ, Al Dandan O, McInnes MD, Flood TA. Ten uncommon and unusual variants of renal angiomyolipoma (AML): radiologic-pathologic correlation. Clinical radiology. 2015 Feb:70(2):206-20. doi: 10.1016/j.crad.2014.10.001. Epub 2014 Nov 15     [PubMed PMID: 25468637]


Park SG, Park BK. New radiologic classification of renal angiomyolipoma: frequently asked questions. Clinical imaging. 2019 May-Jun:55():156-160. doi: 10.1016/j.clinimag.2019.01.025. Epub 2019 Feb 1     [PubMed PMID: 30825810]


Kim JK, Park SY, Shon JH, Cho KS. Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT. Radiology. 2004 Mar:230(3):677-84     [PubMed PMID: 14990834]


Wilson MP, Patel D, Murad MH, McInnes MDF, Katlariwala P, Low G. Diagnostic Performance of MRI in the Detection of Renal Lipid-Poor Angiomyolipomas: A Systematic Review and Meta-Analysis. Radiology. 2020 Sep:296(3):511-520. doi: 10.1148/radiol.2020192070. Epub 2020 Jun 30     [PubMed PMID: 32602827]

Level 1 (high-level) evidence


Forman HP, Middleton WD, Melson GL, McClennan BL. Hyperechoic renal cell carcinomas: increase in detection at US. Radiology. 1993 Aug:188(2):431-4     [PubMed PMID: 8327692]


Ascenti G, Zimbaro G, Mazziotti S, Gaeta M, Settineri N, Scribano E. Usefulness of power Doppler and contrast-enhanced sonography in the differentiation of hyperechoic renal masses. Abdominal imaging. 2001 Nov-Dec:26(6):654-60     [PubMed PMID: 11907734]


Habibollahi P, Sultan LR, Bialo D, Nazif A, Faizi NA, Sehgal CM, Chauhan A. Hyperechoic Renal Masses: Differentiation of Angiomyolipomas from Renal Cell Carcinomas using Tumor Size and Ultrasound Radiomics. Ultrasound in medicine & biology. 2022 May:48(5):887-894. doi: 10.1016/j.ultrasmedbio.2022.01.011. Epub 2022 Feb 23     [PubMed PMID: 35219511]


Steiner MS, Goldman SM, Fishman EK, Marshall FF. The natural history of renal angiomyolipoma. The Journal of urology. 1993 Dec:150(6):1782-6     [PubMed PMID: 8230504]


Yang CW, Shen SH, Chang YH, Chung HJ, Wang JH, Lin AT, Chen KK. Are there useful CT features to differentiate renal cell carcinoma from lipid-poor renal angiomyolipoma? AJR. American journal of roentgenology. 2013 Nov:201(5):1017-28. doi: 10.2214/AJR.12.10204. Epub     [PubMed PMID: 24147472]


Li HM, Yeh LR, Lu K. Renal angiomyolipoma with coexistent hemorrhagic aneurysm formation and fatty thrombus in inferior vena cava: a rare presentation. Abdominal imaging. 2013 Feb:38(1):180-3. doi: 10.1007/s00261-012-9886-2. Epub     [PubMed PMID: 22450723]


Song S, Park BK, Park JJ. New radiologic classification of renal angiomyolipomas. European journal of radiology. 2016 Oct:85(10):1835-1842. doi: 10.1016/j.ejrad.2016.08.012. Epub 2016 Aug 18     [PubMed PMID: 27666625]


Israel GM, Hindman N, Hecht E, Krinsky G. The use of opposed-phase chemical shift MRI in the diagnosis of renal angiomyolipomas. AJR. American journal of roentgenology. 2005 Jun:184(6):1868-72     [PubMed PMID: 15908544]


Sahni VA, Silverman SG. Biopsy of renal masses: when and why. Cancer imaging : the official publication of the International Cancer Imaging Society. 2009 Jul 6:9(1):44-55. doi: 10.1102/1470-7330.2009.0005. Epub 2009 Jul 6     [PubMed PMID: 19602467]


Silverman SG, Gan YU, Mortele KJ, Tuncali K, Cibas ES. Renal masses in the adult patient: the role of percutaneous biopsy. Radiology. 2006 Jul:240(1):6-22     [PubMed PMID: 16709793]


Lobo JM, Clements MB, Bitner DP, Mikula MD, Noona SW, Sultan MI, Cathro HP, Lambert DL, Schenkman NS, Krupski TL. Does renal mass biopsy influence multidisciplinary treatment recommendations? Scandinavian journal of urology. 2020 Feb:54(1):27-32. doi: 10.1080/21681805.2019.1703805. Epub 2019 Dec 23     [PubMed PMID: 31868063]


Ouzaid I, Autorino R, Fatica R, Herts BR, McLennan G, Remer EM, Haber GP. Active surveillance for renal angiomyolipoma: outcomes and factors predictive of delayed intervention. BJU international. 2014 Sep:114(3):412-7. doi: 10.1111/bju.12604. Epub 2014 Apr 16     [PubMed PMID: 24325283]


Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Kwon ED, Leibovich BC. Hormone receptor expression in renal angiomyolipoma: clinicopathologic correlation. Urology. 2008 Oct:72(4):927-32. doi: 10.1016/j.urology.2008.01.067. Epub 2008 Mar 28     [PubMed PMID: 18374399]


Çetin C, Büyükkurt S, Demir C, Evrüke C. Renal angiomyolipoma during pregnancy: Case report and literature review. Turkish journal of obstetrics and gynecology. 2015 Jun:12(2):118-121. doi: 10.4274/tjod.32848. Epub 2015 Jun 15     [PubMed PMID: 28913054]

Level 3 (low-level) evidence


Preece P, Mees B, Norris B, Christie M, Wagner T, Dundee P. Surgical management of haemorrhaging renal angiomyolipoma in pregnancy. International journal of surgery case reports. 2015:7C():89-92. doi: 10.1016/j.ijscr.2015.01.004. Epub 2015 Jan 8     [PubMed PMID: 25598402]

Level 3 (low-level) evidence


Murray TE, Doyle F, Lee M. Transarterial Embolization of Angiomyolipoma: A Systematic Review. The Journal of urology. 2015 Sep:194(3):635-9. doi: 10.1016/j.juro.2015.04.081. Epub 2015 Apr 25     [PubMed PMID: 25916674]

Level 1 (high-level) evidence


Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH, Hofmann F, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A, Bensalah K. Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. European urology oncology. 2020 Feb:3(1):57-72. doi: 10.1016/j.euo.2019.04.005. Epub 2019 Jun 4     [PubMed PMID: 31171501]

Level 1 (high-level) evidence


Zhao Y, Yang Z, Xu W, Ji Z, Dong J. Management of renal tumors during pregnancy: case reports. BMC nephrology. 2021 Apr 9:22(1):127. doi: 10.1186/s12882-021-02318-w. Epub 2021 Apr 9     [PubMed PMID: 33836679]

Level 3 (low-level) evidence


Peng ZF, Yang L, Wang TT, Han P, Liu ZH, Wei Q. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review. The Journal of urology. 2014 Nov:192(5):1424-30. doi: 10.1016/j.juro.2014.04.096. Epub 2014 May 9     [PubMed PMID: 24813310]

Level 1 (high-level) evidence


Watanabe EH, Coelho FMA, Filho HL, Balbo BEP, Neves PDMM, Franzin FM, Yamauchi FI, Onuchic LF. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures. Scientific reports. 2021 Apr 19:11(1):8493. doi: 10.1038/s41598-021-87930-4. Epub 2021 Apr 19     [PubMed PMID: 33875750]


Coombs EJ. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas. Journal of the American Association of Nurse Practitioners. 2013 Nov:25(11):588-96. doi: 10.1002/2327-6924.12081. Epub 2013 Oct 1     [PubMed PMID: 24170533]


Kwiatkowski DJ, Manning BD. Molecular basis of giant cells in tuberous sclerosis complex. The New England journal of medicine. 2014 Aug 21:371(8):778-80. doi: 10.1056/NEJMcibr1406613. Epub     [PubMed PMID: 25140966]


Wang W, Guo H, Shi B, Sun H, Li H, Zhang Y, Cai Y. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex. International urology and nephrology. 2019 Apr:51(4):671-676. doi: 10.1007/s11255-019-02093-6. Epub 2019 Feb 11     [PubMed PMID: 30756282]


Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2013 Mar 9:381(9869):817-24     [PubMed PMID: 23312829]

Level 1 (high-level) evidence


Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert opinion on pharmacotherapy. 2018 Jun:19(8):909-928. doi: 10.1080/14656566.2018.1476492. Epub 2018 May 24     [PubMed PMID: 29757017]

Level 3 (low-level) evidence


Abdelsalam ME, Ahrar K. Ablation of Small Renal Masses. Techniques in vascular and interventional radiology. 2020 Jun:23(2):100674. doi: 10.1016/j.tvir.2020.100674. Epub 2020 May 25     [PubMed PMID: 32591194]


Leflore A, McKenna PH, Schwartz BF. Laparoscopic cryotherapy for pediatric angiomyolipoma: the first report. Journal of endourology. 2007 Mar:21(3):321-4; discussion 324     [PubMed PMID: 17444779]


Johnson SC, Graham S, D'Agostino H, Elmajian DA, Shingleton WB. Percutaneous renal cryoablation of angiomyolipomas in patients with solitary kidneys. Urology. 2009 Dec:74(6):1246-9. doi: 10.1016/j.urology.2008.09.005. Epub 2009 Oct 7     [PubMed PMID: 19815260]


Castle SM, Gorbatiy V, Ekwenna O, Young E, Leveillee RJ. Radiofrequency ablation (RFA) therapy for renal angiomyolipoma (AML): an alternative to angio-embolization and nephron-sparing surgery. BJU international. 2012 Feb:109(3):384-7. doi: 10.1111/j.1464-410X.2011.10376.x. Epub 2011 Dec 16     [PubMed PMID: 22176671]


Prevoo W, van den Bosch MA, Horenblas S. Radiofrequency ablation for treatment of sporadic angiomyolipoma. Urology. 2008 Jul:72(1):188-91. doi: 10.1016/j.urology.2008.02.059. Epub 2008 May 2     [PubMed PMID: 18455777]


Stamatiou KN, Moschouris H, Marmaridou K, Kiltenis M, Kladis-Kalentzis K, Malagari K. Combination of Superselective Arterial Embolization and Radiofrequency Ablation for the Treatment of a Giant Renal Angiomyolipoma Complicated with Caval Thrombus. Case reports in oncological medicine. 2016:2016():8087232. doi: 10.1155/2016/8087232. Epub 2016 May 11     [PubMed PMID: 27293932]

Level 3 (low-level) evidence


Gregory SM, Anderson CJ, Patel U. Radiofrequency ablation of large renal angiomyolipoma: median-term follow-up. Cardiovascular and interventional radiology. 2013 Jun:36(3):682-9. doi: 10.1007/s00270-012-0483-0. Epub 2013 Jan 25     [PubMed PMID: 23354958]


Liu F, Yuan H, Li X, Tang J, Tian X, Ji K. A new management strategy for renal angiomyolipomas: superselective arterial embolization in combination with radiofrequency ablation. Annals of translational medicine. 2019 Dec:7(23):766. doi: 10.21037/atm.2019.11.63. Epub     [PubMed PMID: 32042782]


Nozadze G, Larsen SB, Heerwagen S, Juhl Jensen R, Lönn L, Røder MA. Selective arterial embolization of renal angiomyolipomas: A 10-year experience. BJUI compass. 2022 Jan:3(1):86-92. doi: 10.1002/bco2.107. Epub 2021 Aug 31     [PubMed PMID: 35475158]


Urciuoli P, D'Orazi V, Livadoti G, Foresi E, Panunzi A, Anichini S, Cialini M, Wlderk A, Cirelli C, Colangelo M, Mongardini M, Custureri F. Treatment of renal angiomyolipoma: surgery versus angioembolization. Il Giornale di chirurgia. 2013 Nov-Dec:34(11-12):326-31     [PubMed PMID: 24342162]


Zeid M, Sayedin H, Nabi N, Abdelrahman M, Jacob PT, Alhadi B, Giri S. Active Surveillance for Renal Angiomyolipoma Less Than 4 Centimeters: A Systematic Review of Cohort Studies. Cureus. 2022 Feb:14(2):e22678. doi: 10.7759/cureus.22678. Epub 2022 Feb 28     [PubMed PMID: 35371642]

Level 1 (high-level) evidence


Mues AC, Palacios JM, Haramis G, Casazza C, Badani K, Gupta M, McKiernan J, Benson MC, Landman J. Contemporary experience in the management of angiomyolipoma. Journal of endourology. 2010 Nov:24(11):1883-6. doi: 10.1089/end.2010.0223. Epub 2010 Oct 4     [PubMed PMID: 20919915]


Schieda N, Davenport MS, Pedrosa I, Shinagare A, Chandarana H, Curci N, Doshi A, Israel G, Remer E, Wang J, Silverman SG. Renal and adrenal masses containing fat at MRI: Proposed nomenclature by the society of abdominal radiology disease-focused panel on renal cell carcinoma. Journal of magnetic resonance imaging : JMRI. 2019 Apr:49(4):917-926. doi: 10.1002/jmri.26542. Epub 2019 Jan 28     [PubMed PMID: 30693607]


Hélénon O, Merran S, Paraf F, Melki P, Correas JM, Chrétien Y, Moreau JF. Unusual fat-containing tumors of the kidney: a diagnostic dilemma. Radiographics : a review publication of the Radiological Society of North America, Inc. 1997 Jan-Feb:17(1):129-44     [PubMed PMID: 9017804]


Potretzke AM, Potretzke TA, Bauman TM, Knight BA, Park AM, Mobley JM, Figenshau RS, Siegel CL. Computed Tomography and Magnetic Resonance Findings of Fat-Poor Angiomyolipomas. Journal of endourology. 2017 Feb:31(2):119-128. doi: 10.1089/end.2016.0219. Epub 2017 Jan 3     [PubMed PMID: 27897036]


Jeon HG, Lee SR, Kim KH, Oh YT, Cho NH, Rha KH, Yang SC, Han WK. Benign lesions after partial nephrectomy for presumed renal cell carcinoma in masses 4 cm or less: prevalence and predictors in Korean patients. Urology. 2010 Sep:76(3):574-9. doi: 10.1016/j.urology.2009.11.082. Epub 2010 Mar 29     [PubMed PMID: 20303148]


Geynisman DM, Kadow BT, Shuch BM, Boorjian SA, Matin SF, Rampersaud E, Milestone BN, Plimack ER, Zibelman MR, Kutikov A, Smaldone MC, Chen DY, Viterbo R, Joshi S, Greenberg RE, Malizzia L, McGowan T, Ross EA, Uzzo RG. Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial. The Journal of urology. 2020 Sep:204(3):531-537. doi: 10.1097/JU.0000000000001065. Epub 2020 Apr 6     [PubMed PMID: 32250730]


Krishna S, Murray CA, McInnes MD, Chatelain R, Siddaiah M, Al-Dandan O, Narayanasamy S, Schieda N. CT imaging of solid renal masses: pitfalls and solutions. Clinical radiology. 2017 Sep:72(9):708-721. doi: 10.1016/j.crad.2017.05.003. Epub 2017 Jun 4     [PubMed PMID: 28592361]


Kang SK, Huang WC, Pandharipande PV, Chandarana H. Solid renal masses: what the numbers tell us. AJR. American journal of roentgenology. 2014 Jun:202(6):1196-206. doi: 10.2214/AJR.14.12502. Epub     [PubMed PMID: 24848816]


Dahl DM, Simeone JF, Iliopoulos O, Saylor PJ, Wu CL. Case 36-2018: A 29-Year-Old Man with an Incidentally Discovered Renal Mass. The New England journal of medicine. 2018 Nov 22:379(21):2064-2072. doi: 10.1056/NEJMcpc1802832. Epub     [PubMed PMID: 30462933]

Level 3 (low-level) evidence


Wang LJ, Wong YC, Chen CJ, See LC. Computerized tomography characteristics that differentiate angiomyolipomas from liposarcomas in the perinephric space. The Journal of urology. 2002 Feb:167(2 Pt 1):490-3     [PubMed PMID: 11792904]


Clark PE, Novick AC. Exophytic noninvasive growth pattern of renal angiomyolipomas: implications for nephron sparing surgery. The Journal of urology. 2001 Feb:165(2):513-4     [PubMed PMID: 11176411]


Wang C, Li X, Peng L, Gou X, Fan J. An update on recent developments in rupture of renal angiomyolipoma. Medicine. 2018 Apr:97(16):e0497. doi: 10.1097/MD.0000000000010497. Epub     [PubMed PMID: 29668633]


Restrepo JCÁ, Millan DAC, Sabogal CAR, Bernal AFP, Donoso WD. New Trends and Evidence for the Management of Renal Angiomyolipoma: A Comprehensive Narrative Review of the Literature. Journal of kidney cancer and VHL. 2022:9(1):33-41. doi: 10.15586/jkcvhl.v9i1.177. Epub 2022 Jan 21     [PubMed PMID: 35096516]

Level 3 (low-level) evidence